Future improvements to PARPi could include increased PARP1 specificity to circumvent off-target toxicity [45], decreased PgP efflux to decrease likelihood of this resistance mechanism [46] (see below) and modifications that increase tumour cell-selective PARP1 trapping [22]. Here, PARP1 is linked to neoplasm.